How to Buy Compounded Tirzepatide Safely: The Complete Verification Protocol and Pricing Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide is legal to purchase with a valid prescription from a licensed provider, but only from state-licensed 503A or 503B pharmacies operating under FDA shortage exemptions
• Pricing ranges from $249 to $599 per month depending on dose, pharmacy type, and whether the provider visit is bundled or separate
• Five verification steps (pharmacy license lookup, provider credential check, prescription requirement, ingredient sourcing, sterility documentation) separate legitimate providers from unsafe operations
• The FDA shortage list status determines whether compounding is currently permitted; as of April 2026, tirzepatide remains on the shortage list but this can change with 60 days' notice

Direct answer (40-60 words)

You can buy compounded tirzepatide through telehealth platforms that connect you with licensed providers and state-licensed compounding pharmacies. The process requires a medical consultation, valid prescription, and costs $249 to $599 monthly depending on dose. Verify the pharmacy holds an active state license and operates as a registered 503A or 503B facility before ordering.

Table of contents

1. The legal framework: when compounding tirzepatide is permitted
2. The three pathways to buy compounded tirzepatide
3. Pricing breakdown: what you actually pay
4. The 5-step verification protocol before you order
5. What most articles get wrong about "FDA-approved" vs compounded
6. 503A vs 503B pharmacies: which model is safer
7. The ingredient sourcing question: where the tirzepatide comes from
8. Red flags that signal an unsafe provider
9. The prescription requirement: what's legally necessary
10. Insurance coverage reality check
11. What happens if tirzepatide leaves the shortage list
12. The FormBlends clinical pattern: why patients switch from brand to compounded
13. FAQ
14. Sources
15. Footer disclaimers

The legal framework: when compounding tirzepatide is permitted

Compounded tirzepatide exists in a specific regulatory window. The FDA does not approve compounded medications, but permits pharmacies to compound them under two conditions:

1. Drug shortage exemption. When the FDA places a drug on the shortage list, compounding pharmacies can prepare versions of that drug under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Tirzepatide (the active ingredient in Mounjaro and Zepbound) has been on the FDA shortage list since December 2022 due to manufacturing capacity constraints relative to demand.

1. Valid prescription requirement. Compounding is permitted only in response to an individual patient prescription from a licensed provider. Bulk manufacturing for inventory without patient-specific prescriptions is prohibited under 503A rules (503B facilities have different inventory rules but still require prescriptions for dispensing).

As of April 2026, tirzepatide remains on the shortage list. The FDA updates this list monthly. If Eli Lilly resolves supply constraints and the FDA removes tirzepatide from the shortage list, compounding pharmacies must cease production within 60 days unless they qualify for another exemption (such as a patient-specific medical need that brand-name products don't address, which is rare for tirzepatide).

The practical implication: compounded tirzepatide is currently legal to purchase, but the regulatory window could close. Patients starting compounded tirzepatide should have a contingency plan for transitioning to brand-name products or alternative medications if the shortage resolves.

The three pathways to buy compounded tirzepatide

Pathway 1: Integrated telehealth platforms (most common).

Platforms like FormBlends, and others bundle the provider visit, prescription, and pharmacy fulfillment into a single monthly subscription. You complete an intake form, have a video or asynchronous consultation with a licensed provider in your state, and if appropriate, receive a prescription. The platform's partner pharmacy compounds and ships the medication directly to you.

Pricing: $249 to $599 per month depending on dose, typically includes provider visits, medication, and supplies (syringes, alcohol wipes, sharps container).

Pros: Streamlined, one monthly payment, ongoing provider access.

Cons: You're locked into that platform's pharmacy network. If you want to switch pharmacies, you need a new prescription sent elsewhere.

Pathway 2: Independent provider + independent compounding pharmacy.

You see your own provider (primary care, endocrinologist, obesity medicine specialist), get a prescription, and send it to a compounding pharmacy of your choice. The pharmacy ships the medication to you.

Pricing: Provider visit $150 to $300 (often not covered by insurance for weight loss), medication $200 to $450 per month depending on dose and pharmacy, supplies $15 to $30.

Pros: Full control over provider and pharmacy choice.

Cons: More coordination required, separate billing from provider and pharmacy.

Pathway 3: In-person provider + local compounding pharmacy.

Same as pathway 2, but you pick up the medication in person from a local compounding pharmacy instead of mail order.

Pricing: Similar to pathway 2.

Pros: Immediate access to pharmacist for questions, no shipping delays.

Cons: Requires a local compounding pharmacy (not available in all areas), in-person pickup every month.

Most patients use pathway 1 due to convenience and cost transparency. Pathway 2 is common for patients who already have an established relationship with a provider who prescribes GLP-1 medications.

Pricing breakdown: what you actually pay

Compounded tirzepatide pricing is not standardized. Here's the typical range as of April 2026:

Dose	Monthly cost (telehealth platform)	Monthly cost (independent pharmacy)	Brand-name equivalent retail price
2.5 mg weekly	$249 to $349	$200 to $300	$1,069 (Mounjaro/Zepbound)
5 mg weekly	$299 to $399	$250 to $350	$1,069
7.5 mg weekly	$349 to $449	$300 to $400	$1,069
10 mg weekly	$399 to $499	$350 to $450	$1,069
12.5 mg weekly	$449 to $549	$400 to $500	$1,069
15 mg weekly	$499 to $599	$450 to $550	$1,069

The brand-name price is consistent across doses because Eli Lilly prices by pen, not by milligram content. Compounded pricing scales with dose because higher doses require more active ingredient.

What's included in telehealth platform pricing:

• Initial provider consultation
• Ongoing provider access (usually asynchronous messaging, some platforms include follow-up video visits)
• Compounded tirzepatide vial (typically 4 to 5 weekly doses per vial)
• Syringes, alcohol wipes, sharps container
• Shipping

What's NOT included:

• Initial lab work if required (some providers require baseline A1C, lipid panel, liver function tests)
• Follow-up lab work
• Treatment for side effects beyond standard provider consultation

The cost difference between compounded and brand-name is the primary driver of demand. Even at the high end ($599/month), compounded tirzepatide is 44% cheaper than brand-name retail. For patients without insurance coverage or whose insurance doesn't cover GLP-1 medications for weight loss, the savings are $470 to $820 per month.

The 5-step verification protocol before you order

The compounding pharmacy industry includes both highly regulated, quality-focused operations and less scrupulous ones. The verification protocol below separates the two.

Step 1: Verify the pharmacy holds an active state license.

Every state requires compounding pharmacies to hold a pharmacy license. Look up the pharmacy's license on your state board of pharmacy website. Verify:

• License is active (not expired, suspended, or revoked)
• Pharmacy name and address match what the provider or platform told you
• No disciplinary actions in the past 24 months

If the platform or provider won't tell you which specific pharmacy will fill your prescription, that's a red flag. Legitimate operations disclose their pharmacy partners.

Step 2: Confirm 503A or 503B registration.

Compounding pharmacies operate under one of two FDA frameworks:

• 503A pharmacies compound patient-specific prescriptions, can't advertise specific compounded drugs, and are primarily regulated by state boards of pharmacy.
• 503B outsourcing facilities register with the FDA, undergo FDA inspections, can compound larger batches, and must follow current good manufacturing practices (cGMP).

Ask the pharmacy directly: "Are you a registered 503B facility, or do you operate under 503A?" Either is acceptable, but 503B facilities undergo more rigorous federal oversight. You can verify 503B registration on the FDA's outsourcing facilities list (publicly available on FDA.gov).

Step 3: Verify prescription requirement.

Legitimate compounding pharmacies will not dispense tirzepatide without a valid prescription from a licensed provider. If a website offers to sell you tirzepatide without a provider consultation or prescription, it's operating illegally.

The consultation must be with a provider licensed in your state. Some telehealth platforms use providers licensed in multiple states; verify the provider who writes your prescription holds an active license in your state of residence.

Step 4: Ask about ingredient sourcing.

Compounding pharmacies source tirzepatide active pharmaceutical ingredient (API) from FDA-registered suppliers. Ask: "Where do you source your tirzepatide API, and can you provide a certificate of analysis?"

A certificate of analysis (CoA) is a document from the supplier verifying the purity, potency, and sterility of the API batch. Legitimate pharmacies can provide this on request (they may redact proprietary supplier information, which is normal).

If the pharmacy refuses to disclose anything about ingredient sourcing or says "that's proprietary," consider it a yellow flag. Transparency on sourcing is standard in reputable compounding.

Step 5: Confirm sterility testing.

Compounded tirzepatide is an injectable medication, which means it must be sterile. Ask: "Do you perform sterility testing on each batch, and what's your testing protocol?"

503B facilities are required to perform sterility testing per FDA regulations. 503A pharmacies are not federally required to test every batch but many do as a quality measure. The answer you want to hear includes specific testing methods (e.g., USP <71> sterility testing, endotoxin testing) and batch documentation.

If the pharmacy says "we follow all regulations" without specifics, push for details. Legitimate pharmacies are proud of their testing protocols and will explain them.

What most articles get wrong about "FDA-approved" vs compounded

The most common error in articles about compounded tirzepatide is the phrase "compounded tirzepatide is not FDA-approved, so it's less safe than brand-name."

This conflates two separate things: FDA approval and safety.

FDA approval is a regulatory designation that applies to a specific formulation manufactured by a specific company under a New Drug Application (NDA). Mounjaro and Zepbound are FDA-approved tirzepatide products manufactured by Eli Lilly.

Compounded medications are not FDA-approved because they're not manufactured under an NDA. They're prepared by pharmacies under a different regulatory framework (503A or 503B). The FDA does not review or approve individual compounded preparations.

But "not FDA-approved" does not mean "unregulated" or "unsafe." Compounding pharmacies are regulated by state boards of pharmacy and (in the case of 503B facilities) by the FDA under different rules than drug manufacturers. They must follow USP (United States Pharmacopeia) standards for sterile compounding, maintain clean rooms, document ingredient sourcing, and in many cases perform batch testing.

The safety question is not "approved vs not approved." It's "does this specific pharmacy follow proper compounding standards?" A 503B facility with regular FDA inspections, documented sterility testing, and transparent sourcing can produce a product that's functionally equivalent in safety to a brand-name drug. A 503A pharmacy operating out of a strip mall with no sterility testing cannot.

The error most articles make is treating all compounded tirzepatide as a monolith. The variance within the compounded category is larger than the difference between high-quality compounded and brand-name products.

The correct framing: compounded tirzepatide is not FDA-approved, which means the burden is on you to verify the pharmacy's quality standards before ordering. Brand-name products remove that verification burden because the FDA has done it for you.

503A vs 503B pharmacies: which model is safer

The practical differences:

Feature	503A pharmacy	503B outsourcing facility
FDA registration	Not required	Required
FDA inspections	Rare (state inspections only)	Regular (risk-based schedule)
Batch size limits	Yes (patient-specific only)	No (can compound larger batches for inventory)
Sterility testing	Not federally required (state-dependent)	Required for every batch
cGMP compliance	Not required	Required
Advertising restrictions	Cannot advertise specific compounded drugs	Can advertise
State pharmacy license	Required	Required

Which is safer? 503B facilities undergo more rigorous oversight and mandatory sterility testing, which reduces contamination risk. The 2012 fungal meningitis outbreak that killed 64 people and sickened 750+ was traced to a compounding pharmacy operating under 503A rules without adequate sterility controls. That outbreak led to the creation of the 503B framework.

That said, many 503A pharmacies voluntarily follow 503B-equivalent standards (sterility testing, cGMP, clean room protocols) even though they're not required to. The pharmacy's actual practices matter more than the regulatory category.

What to ask: "Are you a 503B facility? If you're 503A, do you perform sterility testing on every batch and follow USP <797> and <800> standards?"

If the answer is yes to either question, you're in good shape. If the answer is "we're 503A and we follow state regulations," ask specifically about sterility testing and clean room protocols.

Most telehealth platforms partner with 503B facilities because the regulatory overhead is higher but the liability risk is lower. Independent compounding pharmacies are more likely to be 503A.

The ingredient sourcing question: where the tirzepatide comes from

Compounding pharmacies do not synthesize tirzepatide from scratch. They purchase tirzepatide active pharmaceutical ingredient (API) from suppliers, then compound it into injectable formulations.

The API supply chain has three tiers:

Tier 1: FDA-registered U.S. suppliers. These suppliers operate under FDA oversight, provide certificates of analysis for every batch, and are the same suppliers that provide API to brand-name manufacturers for non-tirzepatide products. This is the gold standard.

Tier 2: International suppliers registered with their home country's regulatory body (e.g., EMA in Europe, PMDA in Japan). These suppliers meet international pharmaceutical standards and provide CoAs. Quality is generally high but oversight is one step removed from FDA.

Tier 3: Unregistered or minimally regulated international suppliers. These suppliers may provide API at lower cost but with less documentation and no regulatory oversight. This is where quality and safety risks concentrate.

Legitimate compounding pharmacies use Tier 1 or Tier 2 suppliers exclusively. If a pharmacy won't disclose its supplier tier or provides evasive answers, assume Tier 3 and walk away.

The question to ask: "Is your tirzepatide API sourced from an FDA-registered supplier, and can you provide the certificate of analysis?"

The answer should be yes. If the pharmacy says "our suppliers are proprietary" or "we can't disclose that," it's a red flag. Transparency on sourcing is standard practice in quality compounding.

Red flags that signal an unsafe provider

Red flag 1: No prescription required, or "prescription included" without a real consultation.

If a website lets you buy tirzepatide by filling out a form without speaking to or messaging with a licensed provider, it's illegal. The consultation can be asynchronous (written intake form reviewed by a provider), but there must be a provider review and prescription.

"Prescription included" is fine if it means "we connect you with a provider who will evaluate you and prescribe if appropriate." It's not fine if it means "we'll generate a prescription automatically."

Red flag 2: Won't disclose which pharmacy fills the prescription.

Legitimate platforms tell you upfront which pharmacy or pharmacies they partner with. If the platform says "we use a network of pharmacies" but won't name them, you can't verify their licenses or quality standards.

Red flag 3: Prices far below market ($150/month or less).

Compounded tirzepatide has a floor cost based on API pricing, compounding labor, sterility testing, and shipping. If a provider offers tirzepatide for $150/month or less, either they're cutting corners on quality (Tier 3 API, no sterility testing, minimal provider oversight) or it's a bait-and-switch (the $150 doesn't include required add-ons).

Market rate is $249 to $599/month depending on dose. Prices 40% below that floor are suspicious.

Red flag 4: No provider access after the initial prescription.

GLP-1 medications require ongoing monitoring for side effects, dose adjustments, and lab work. If the provider relationship ends after the initial prescription and you're just reordering medication without check-ins, that's substandard care.

Legitimate platforms include ongoing provider access (messaging, follow-up visits, dose adjustment consultations) in the monthly fee.

Red flag 5: Marketing claims that sound like drug advertising.

503A pharmacies are prohibited from advertising specific compounded drugs. If a website has ad copy like "Get compounded tirzepatide, the same medication as Mounjaro, for 70% less," that's a 503A violation (503B facilities can advertise, but they can't claim equivalence to brand-name drugs).

Legitimate platforms describe the service ("weight loss medication prescribed by licensed providers") without specific drug advertising.

Red flag 6: Offshore pharmacies or "international shipping."

U.S. patients must receive compounded medications from U.S.-licensed pharmacies. If the pharmacy is based outside the U.S. or offers "international shipping," it's not operating under U.S. regulations. The medication may be counterfeit, contaminated, or contain incorrect doses.

Only order from pharmacies with a physical U.S. address and active state pharmacy license.

The prescription requirement: what's legally necessary

To legally obtain compounded tirzepatide, you need:

1. A consultation with a licensed provider. The provider must be licensed in your state of residence. The consultation can be in-person, video, or asynchronous (written intake form), but it must include a medical history review and clinical decision-making.

1. A valid prescription. The prescription must include your name, the provider's name and DEA number (if applicable), the medication name and dose, directions for use, and the pharmacy name. Tirzepatide is not a controlled substance, so no special DEA requirements apply beyond standard prescription rules.

1. An appropriate medical indication. Providers prescribe tirzepatide for type 2 diabetes (FDA-approved indication for Mounjaro) or obesity/weight management (FDA-approved indication for Zepbound). Off-label prescribing for weight loss in overweight patients without obesity is common and legal, but the provider must document a medical rationale.

What's NOT required:

• In-person visit (telehealth is legal in all 50 states for tirzepatide as of April 2026)
• Prior authorization (for compounded medications, since they're not billed to insurance)
• Diabetes diagnosis (providers can prescribe for weight loss alone)

The provider's clinical judgment determines whether tirzepatide is appropriate. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease. Relative contraindications include history of pancreatitis, active gallbladder disease, and pregnancy.

If you don't meet criteria (e.g., BMI under 27 with no weight-related comorbidities, or contraindications present), a legitimate provider will decline to prescribe. Platforms that approve everyone regardless of medical history are operating outside standard-of-care guidelines.

Insurance coverage reality check

Compounded tirzepatide is not covered by insurance. Here's why:

1. Insurance covers FDA-approved medications. Compounded medications are not FDA-approved, so they fall outside the formulary system.

1. Compounding pharmacies don't contract with insurance. Most compounding pharmacies operate on a cash-pay model. They don't submit claims to insurance companies.

1. Even brand-name tirzepatide has limited coverage. Mounjaro is covered for type 2 diabetes by most plans (often with prior authorization). Zepbound is covered for obesity by fewer plans, and many exclude coverage for weight loss medications entirely.

Some patients try to get reimbursed by submitting receipts to their insurance company for out-of-network pharmacy benefits. Success rate is low (under 10% based on patient reports in online communities), and even when successful, reimbursement is partial.

HSA/FSA eligibility: Compounded tirzepatide prescribed for a medical condition (obesity, type 2 diabetes) is an eligible expense for Health Savings Accounts and Flexible Spending Accounts. You can use HSA/FSA funds to pay for the medication and provider visits. This doesn't reduce the cost but allows you to pay with pre-tax dollars, which is a 20% to 35% effective discount depending on your tax bracket.

The insurance coverage landscape could change. If tirzepatide leaves the shortage list and compounding ceases, patients would need to transition to brand-name products. At that point, insurance coverage becomes relevant. Brand-name Mounjaro and Zepbound retail for $1,069/month but are often covered with copays ranging from $25 to $500/month depending on the plan.

What happens if tirzepatide leaves the shortage list

The FDA updates the drug shortage list monthly. When a drug is removed from the list, compounding pharmacies must stop producing it within 60 days unless they qualify for an exemption.

The most likely timeline: Eli Lilly has expanded manufacturing capacity throughout 2024 and 2025. If supply catches up to demand, the FDA could remove tirzepatide from the shortage list in late 2026 or 2027.

What happens to patients on compounded tirzepatide:

Scenario 1: Transition to brand-name. You'd switch from compounded tirzepatide to Mounjaro (for diabetes) or Zepbound (for weight loss). Your provider would write a new prescription. If you have insurance coverage, your out-of-pocket cost might be lower than compounded (if your copay is under $249/month). If you don't have coverage, your cost jumps to $1,069/month retail, though Eli Lilly offers a savings card that reduces cost to $550/month for commercially insured patients.

Scenario 2: Switch to a different GLP-1 medication. Semaglutide (Ozempic, Wegovy) is also on the FDA shortage list as of April 2026. If semaglutide remains available for compounding, you could switch to compounded semaglutide. Alternatively, your provider might prescribe a different weight-loss medication (phentermine, naltrexone/bupropion, liraglutide).

Scenario 3: Compounding continues under an exemption. In rare cases, compounding can continue for patients with documented medical need that brand-name products don't address (e.g., allergy to an inactive ingredient in the brand-name formulation). This applies to under 1% of patients.

The practical advice: if you start compounded tirzepatide, have a contingency plan. Know whether your insurance covers brand-name Mounjaro or Zepbound. If not, budget for the possibility of switching to a different medication or paying brand-name retail prices.

Most telehealth platforms will help coordinate the transition if the shortage resolves. Ask upfront: "What happens if tirzepatide leaves the shortage list while I'm a patient?"

The FormBlends clinical pattern: why patients switch from brand to compounded

Across thousands of patient intake forms, the most common reason patients switch from brand-name tirzepatide to compounded is insurance coverage loss or denial.

The typical pattern:

1. Patient starts Mounjaro or Zepbound with insurance coverage (copay $25 to $100/month)
2. Insurance denies refill authorization after 3 to 6 months, citing lack of documented weight loss, failure to meet step therapy requirements, or policy change
3. Patient faces $1,069/month retail price
4. Patient switches to compounded tirzepatide at $299 to $499/month

The second most common pattern is patients who were never able to get insurance coverage in the first place. Many insurance plans exclude weight-loss medications entirely, even for patients with obesity and comorbidities. These patients start directly on compounded tirzepatide.

A smaller but growing pattern: patients who prefer compounded formulations because they include added ingredients (B12, B6, or other vitamins) that brand-name products don't contain. Some compounding pharmacies offer tirzepatide formulations with methylcobalamin (B12) added, which patients report helps with energy levels during calorie restriction. This is anecdotal; no published studies compare outcomes between standard tirzepatide and vitamin-enhanced compounded versions.

What we don't see often: patients switching from brand to compounded due to dissatisfaction with brand-name efficacy or side effects. The active ingredient is the same; switching formulations doesn't typically change response. Patients who don't tolerate tirzepatide usually switch to semaglutide or a different medication class entirely, not to a different tirzepatide formulation.

The pattern reinforces that compounded tirzepatide demand is primarily cost-driven, not preference-driven. If brand-name tirzepatide were priced at $300/month, compounded demand would collapse.

FAQ

Is it legal to buy compounded tirzepatide? Yes, with a valid prescription from a licensed provider. Compounding pharmacies can legally prepare tirzepatide while it remains on the FDA drug shortage list. Purchasing without a prescription or from unlicensed sources is illegal.

How much does compounded tirzepatide cost per month? $249 to $599 per month depending on dose, provider, and pharmacy. Lower doses (2.5 mg to 5 mg weekly) cost $249 to $399. Higher doses (10 mg to 15 mg weekly) cost $399 to $599. This typically includes the medication, provider visits, and supplies.

Is compounded tirzepatide the same as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not manufactured by Eli Lilly and is not FDA-approved. Quality depends on the compounding pharmacy's standards. High-quality compounded tirzepatide from a 503B facility is functionally similar to brand-name products.

Do I need a prescription to buy compounded tirzepatide? Yes. Compounded tirzepatide is a prescription medication. Legitimate providers require a consultation with a licensed provider who will evaluate your medical history and write a prescription if appropriate.

Can I use my insurance to pay for compounded tirzepatide? No. Compounded medications are not covered by insurance because they're not FDA-approved. You may be able to use HSA or FSA funds to pay for it, which provides a tax advantage.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies are state-regulated and compound patient-specific prescriptions. 503B outsourcing facilities are FDA-registered, undergo regular FDA inspections, and must perform sterility testing on every batch. Both are legal; 503B facilities have more rigorous oversight.

How do I verify a compounding pharmacy is legitimate? Check the pharmacy's state license on your state board of pharmacy website. Verify it's active with no recent disciplinary actions. Ask if it's a 503B facility (verify on the FDA outsourcing facilities list). Request information about ingredient sourcing and sterility testing.

What happens if the FDA removes tirzepatide from the shortage list? Compounding pharmacies must stop producing tirzepatide within 60 days. You'd need to transition to brand-name Mounjaro or Zepbound, switch to a different medication, or qualify for a medical exemption (rare).

Can I buy compounded tirzepatide without a video visit? Yes. Many telehealth platforms use asynchronous consultations (written intake forms reviewed by a provider). You don't need a live video visit, but you do need a provider to review your medical history and write a prescription.

Is compounded tirzepatide safe? Safety depends on the compounding pharmacy's quality standards. Pharmacies that follow USP sterile compounding standards, perform batch sterility testing, and source API from FDA-registered suppliers produce safe products. Pharmacies that cut corners on these standards pose contamination and dosing accuracy risks.

How long does compounded tirzepatide last after mixing? Most compounded tirzepatide formulations are stable for 28 to 60 days after reconstitution when refrigerated at 36°F to 46°F. Check the pharmacy's specific beyond-use date (BUD) on the vial label. Do not use medication past the BUD.

Can I travel with compounded tirzepatide? Yes. Carry it in a cooler with ice packs if traveling longer than 2 hours. TSA allows medications in carry-on luggage. Bring your prescription label in case you're asked to verify it's prescribed to you. For international travel, check the destination country's rules on importing prescription medications.

What if I have side effects from compounded tirzepatide? Contact your provider immediately for severe side effects (persistent vomiting, severe abdominal pain, signs of pancreatitis). For mild side effects (nausea, constipation, fatigue), your provider can adjust your dose or recommend management strategies. Most side effects resolve within 2 to 4 weeks.

Do compounding pharmacies add anything besides tirzepatide? Some pharmacies offer formulations with added B12 or B6. Others use only tirzepatide and standard inactive ingredients (sodium chloride, water for injection). Ask the pharmacy for a complete ingredient list if you have allergies or sensitivities.

Can I switch from brand-name to compounded tirzepatide without changing doses? Yes. If you're stable on Mounjaro 10 mg weekly, you can switch to compounded tirzepatide 10 mg weekly without retitration. Confirm with your provider, but dose-for-dose switching is standard practice.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. FDA Drug Shortages Database. Updated monthly. Accessed April 2026.
4. Federal Food, Drug, and Cosmetic Act, Section 503A and 503B. USC Title 21.
5. United States Pharmacopeia Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2019.
6. United States Pharmacopeia Chapter 800: Hazardous Drugs - Handling in Healthcare Settings. 2020.
7. FDA Outsourcing Facilities List. Updated quarterly. Accessed April 2026.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. American Society of Health-System Pharmacists. Tirzepatide shortage documentation. 2023-2026.
10. National Association of Boards of Pharmacy. Compounding pharmacy regulations by state. 2025.
11. Davies M et al. Gastric emptying and glucose metabolism with tirzepatide versus placebo. Diabetes Care. 2023.
12. CDC. Multistate Outbreak of Fungal Meningitis and Other Infections. Case summary 2012-2013.
13. Eli Lilly and Company. Mounjaro and Zepbound prescribing information. Updated 2025.
14. American College of Gastroenterology. Obesity management guidelines. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.